Webinar: ASCO 2023 Update: BCA101 With Pembrolizumab Dose Expansion Results in Patients With R/M HNSCC

Bicara Therapeutics Inc. published this content on June 05, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 02, 2025 at 10:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]